RG 012

Drug Profile

RG 012

Alternative Names: RG 456070; RG012; SAR 339375

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regulus Therapeutics; Sanofi
  • Developer Regulus Therapeutics
  • Class Antisense oligoribonucleotides; Urologics
  • Mechanism of Action MicroRNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary nephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hereditary nephritis

Most Recent Events

  • 07 Nov 2017 Regulus initiates enrolment in a phase I renal biopsy trial for Hereditary nephritis
  • 04 May 2017 Preliminary adverse events and pharmacokinetics data from the phase I MAD trial in healthy volunteers released by Regulus Therapeutics
  • 02 Mar 2017 Regulus Therapeutics plans a phase I/II renal biopsy pharmacokinetics trial in Hereditary nephritis patients
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top